HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Humacyte, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.40−0.03 (-6.50%)

Close on Oct 19, 2026

Market cap: $93.93M
P/E (TTM): –
Dividend yield: –

Humacyte, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	50	95	81	150	218	40	94
Short-Term Investments	–	–	0	2.11	8.00	0	–
Cash & Short-Term Investments	50	95	80	152	226	40	94
Receivables	0.44	0	0	0.03	0.18	0.11	–
Inventory	14	0	–	–	–	–	–
Prepaid Expenses & Other	3.27	2.92	2.83	2.30	3.66	1.41	–
Total Current Assets	68	48	83	154	229	41	–
Property, Plant & Equipment	19	23	27	30	35	41	–
Gross Property, Plant & Equipment	60	59	58	56	55	55	–
Accumulated Depreciation	-41	-36	-31	-26	-20	-14	–
Long-Term Investments	–	–	–	–	–	100	–
Operating Lease Right-of-Use Assets	0	0.60	0.60	0.70	0.73	0.77	–
Other Long-Term Assets	0.67	1.25	0.63	0.68	–	–	–
Total Assets	116	138	128	204	287	107	–
Accounts Payable	5.40	4.49	6.49	1.60	2.09	2.27	–
Accrued Expenses	11	11	9.34	7.11	6.76	4.59	–
Current Portion of Leases	–	–	0.05	0.05	0.05	0.04	–
Other Current Liabilities	0	0.24	0.05	–	–	–	–
Total Current Liabilities	18	20	18	20	11	11	–
Long-Term Leases	–	0.50	0.60	0.60	0.68	0.73	–
Operating Lease Liabilities	0	0.60	0.60	0.70	0.70	0.80	–
Deferred Tax Liabilities	0.76	1.16	1.52	1.86	2.24	1.91	–
Other Long-Term Liabilities	1.58	0.98	0.71	0.71	–	–	–
Total Liabilities	113	191	115	87	164	36	–
Preferred Stock	0	0	0	0	0	0	–
Common Stock	0.02	0.01	0.01	0.01	0.01	0.00	–
Additional Paid-In Capital	730	633	551	543	537	38	–
Retained Earnings	-727	-686	-537	-427	-415	-388	–
Shareholders' Equity	3.11	-53	14	117	122	-350	-289
Total Equity	3.11	-53	14	117	122	-350	-289
Total Liabilities & Equity	116	138	128	204	287	107	–
Shares Outstanding(shares)	193	130	104	103	103	5.82	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -494.6%
Operating margin: -5240.8%
Net margin: -4560.8%
Return on equity, FY2025: 164.8%

Financial strength

Current ratio: 6.21
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 534.5%

Valuation

P/E ratio: –
Price to sales: 44.29
Price to book: 3.00
Dividend yield: –